Proactive Investors - Run By Investors For Investors

Hemispherx Biopharma launches $8M rights issue to fund cancer drug trials

The company is making great strides in using its therapy Ampligen as an immuno-oncology agent to fight multiple types of cancer
cancer in headline
Under the offering, shareholders can purchase up to 8,000 units at $1,000 each

Hemispherx Biopharma Inc (NYSE American:HEB) has lodged a prospectus for an $8 million rights offering to purchase up to 8,000 units at $1,000 each as it looks to raise money to fund trials for its anti-cancer agent Ampligen.

Under the proposed rights offering, Hemispherx will distribute to its shareholders and to holders of certain options and warrants as of February 14, one non-transferable subscription right for each share of stock held on the record date.

READ: Hemispherx Biopharma's cancer drug Ampligen to be used in new oncology study

Each right permits the shareholder to purchase one unit at a subscription price of $1,000, consisting of one share of Series B Convertible Preferred stock (with a face value of $1,000) and 4,000 five-year warrants, each with an exercise price of $0.25.

“We are extremely pleased with the progress to date, moving Ampligen into immuno-oncology clinical trials for evaluation as an anti-cancer agent. Our use of a rights offering allows those stockholders who participate in the offering to help fund the Company and benefit from our future work,” said Thomas Equels, CEO of Hemispherx, in a statement.

The rights offering is expected to expire on or about March 1, 2019. Maxim Group and Ascendiant Capital Markets LLC have been hired as dealer-managers in the rights offering.

Hemispherx’s flagship products include the Argentina-approved Ampligen, which treats chronic fatigue syndrome and cancer, and the FDA-approved drug Alferon N Injection, a treatment for genital warts.

Hemispherx shares closed up by 11% to hit $0.26 on Wednesday.

Contact Ellen Kelleher at [email protected]


View full HEB profile View Profile

Hemispherx Biopharma Inc Timeline

Related Articles

October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
scientist at petrie dish
Here we take a closer look at Midatech Pharma PLC (LON:MTPH)
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use